Press releaseACCESS Newswire
Lexaria Bioscience
LEXX · NASDAQ
$3.08+$0.09 (+3.01%)TodayMarket closed ·
Prev close $2.99
Latest news
- Press releaseACCESS Newswire
Lexaria Announces Results from Animal Study GLP-1-A26-1
- Press releaseACCESS Newswire
GLP-1 Weight-Loss/Diabetes Industries Continue Transition to Oral Medications
- Press releaseACCESS Newswire
Lexaria Updates Financial Position
- News
12 Health Care Stocks Moving In Monday's After-Market Session
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- Press releaseACCESS Newswire
Lexaria Announces Closing of Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- News
12 Health Care Stocks Moving In Tuesday's After-Market Session
- NewsAvi Kapoor
Crude Oil Gains 1.5%; ABM Posts Upbeat Q3 Earnings
- NewsAvi Kapoor
Dow Tumbles 450 Points; US Small Business Sentiment Declines In August
- Press releaseACCESS Newswire
Lexaria Announces Exercise of Warrants for Approximately $5.9 Million in Gross Proceeds
- Press releaseACCESS Newswire
Lexaria to Present at the H.C. Wainwright 28th Annual Global Investment Conference
- Press releaseACCESS Newswire
Lexaria Receives USD$2.6 Million Tax Rebate Payment
- Press releaseACCESS Newswire
DehydraTECH(TM)-enhanced Amycretin and Retatrutide Yield Significant Absorption Improvements in Lexaria's 2026 Animal Study #2
- News
12 Health Care Stocks Moving In Monday's After-Market Session
- NewsHenry Khederian
Lexaria Bioscience Stock Rallies Thursday: What Investors Need to Know
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- News
12 Health Care Stocks Moving In Monday's After-Market Session
- News
12 Health Care Stocks Moving In Wednesday's Intraday Session
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- Press releaseGlobe Newswire
THE FOCUS DOCTRINE: 5 Assets Securing the 2026 Biological Choke Point
- Press releaseACCESS Newswire
Lexaria Releases Annual Letter from the CEO
- NewsAvi Kapoor
Why Bark Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket
- NewsAvi Kapoor
Capital One Financial To Rally More Than 24%? Here Are Top Analyst Forecasts For Friday
- NewsVandana Singh
Lexaria Says Oral GLP-1 Cuts Side Effects Nearly 50% Versus Novo Nordisk's Rybelsus
- NewsAvi Kapoor
Nasdaq Gains 100 Points; US Consumer Sentiment Falls
- NewsAvi Kapoor
Dow Jumps Over 250 Points; Fed's Key Inflation Gauge Remains Hot
- NewsAvi Kapoor
Why Top KingWin Shares Are Trading Higher By 87%; Here Are 20 Stocks Moving Premarket
- News
Watching Lexaria Bioscience; Zacks Small-Cap Research Gives Stock $8 Price Valuation
- NewsAvi Kapoor
Crude Oil Edges Higher; Phillips 66 Posts Wider-Than-Expected Loss
- NewsAvi Kapoor
Dow Falls 200 Points; Alphabet Posts Upbeat Q1 Results
- News
Lexaria Bioscience Issues Glucagon-like Peptide-1 Strategic Update; Says Its Proprietary DehydraTECH Technology Could Enhance Performance And Lower Side Effects
- Press releaseACCESS Newswire
Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience's Technology
- Press releaseACCESS Newswire
Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm
- Press releaseACCESS Newswire
Lexaria Releases Annual Letter from the CEO
- Press releaseACCESSWIRE
Lexaria Releases Strategic Letter from the Outgoing CEO
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.